// App-Quantinova.ai

: Pelvic SABR with HDR boost in intermediate- and high-risk prostate cancer (SPARE): Favorable early toxicity and quality-of-life outcomes.

Researchers

Presenter

  • Hima Bindu Musunuru

Principal Investigators

  • Andrea Deabreu

  • Melanie Davidson

  • Ananth Ravi

  • Joelle Antoine Helou

  • Ling Ho

  • Patrick Cheung

  • Danny Vesprini

  • Stanley K. Liu

  • William Chu

  • Renee Korol

  • Hans T. Chung

  • Alexandre Mamedov

  • Liying Zhang

  • Andrew Loblaw

Medical Centers

  • Deapertment of Radiation Oncology, Sunnybrook Health Sciences, University of Toronto, Toronto, ON, Canada

  • Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Sunnybrook Hospital, Radiation Oncology, University of Toronto, Toronto, ON, Canada

  • Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

  • Sunnybrook Odette Cancer Centre, Toronto, ON, Canada

  • Toronto-Sunnybrook Reg Cancer Centre, Toronto, ON, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved